Commentary

Iron Therapy in Pregnant Women

Iosief Abraha*

Mauro Marchesi Immunotransfusion Service, Perugia Hospital Company, Perugia, Italy

Pregnancy is characterized by a remarkable maternal physiological change with an intense fetal growth that needs adequate nutrition. Epidemiological evidence suggest that between 11% and 45% of women in Western countries of child-bearing age have depleted iron stores [1] and this explains why most pregnant women are found with totally depleted iron stores. Limited iron stores may lead to iron deficiency that is the most leading cause of anemia in pregnancy [2]. The prevalence of iron deficiency in pregnancy depends much on the economic status of the population and it varies from 20% to 90% [3].

Observational studies suggest that iron deficiency without anemia has important implications to the child and mother health. For example, some report a strong correlation between low maternal serum ferritin concentrations and iron deficiency anemia in neonates [4,5] which may lead to consequence on motor, social-emotional, and neurophysiologic development [6] as well as a long lasting implication on cognitive and behavioral abnormalities [7]. Iron deficiency anemia is reported to lead to several adverse consequences the mother and child health described in the medical literature. These include increased rates for cesarean delivery, prematurity birth, low infant birth weight perinatal bleeding, preeclampsia, placental abruption, poor maternal thyroid status, cardiac failure, and mortality as well as poor wound healing and increased demand of transfusion [6, 8-11]. Despite the quality of the evidence concerning these negative consequences has not been completely addressed and some adverse effects has not been confirmed in other studies [12], screening for maternal iron deficiency should be mandatory.

Screening can be performed by readily available inexpensive tests that include serum ferritin, total iron binding capacity, and percent transferrin saturation (TSAT). Total iron binding capacity and TSAT are required because serum ferritin can falsely be increased during morbidities such as autoimmune diseases. Iron deficiency is considered present when TSAT<20% and/or ferritins<30 ng/mL.

There is a preponderance of published studies in the medical literature addressing the efficacy of iron therapies to treat or prevent outcomes in pregnancy. A recent systematic overview of reviews identified 11 studies that encompassed 31 randomized trials with over 40000 participants and an impressive number of outcomes [13]. A multidisciplinary panel was able to prioritize critical maternal and neonatal outcomes using the Delphi method. Critical maternal outcomes resulted in incidence of anemia (defined as Hb<11 gr/dl) and iron deficiency anemia. Pooled data from 14 studies with 3831 participants showed that iron based interventions may reduce the incidence of anemia by 62% (RR 0.38 (95% CI 0.26 to 0.53) with a number needed-to-treat (NNT) of 4. This evidence was however judged low according to the GRADE method [14] due to important heterogeneity and serious concerns in terms of risk of bias. Heterogeneity could be attributed to several factors including differences in doses of the interventions (iron therapies varied from 30 mg to 1000 mg per day), Hb level at study entry (ranging between ≥ 10 gr/dl and ≥ 13.2 gr/dl), other inclusion criteria of the population as well as setting (the trials were performed in several different countries across the globe). Investigation of the heterogeneity did not provide any solution, however, subgroup analysis limited to the studies with low risk of bias confirmed that iron based therapies can reduce the risk of anemia by 59% (RR 0.41 (95% CI 0.23 to 0.73)) with an unchanged NNT. The level of evidence was thus judged moderate which means that it is likely that further evidence can change the confidence in the treatment effect.

Analysis regarding iron deficiency anemia, the second maternal outcome, confirmed that iron reduced iron deficiency anemia by 67% (RR 0.33, 95% CI 0.16 to 0.69) albeit low level evidence (due to very serious concern in terms of risk of bias). However, no evidence of difference was observed in terms of preterm birth, neonatal death and low birth weight with a low quality of evidence despite adequate number of participants (at least 15,000 for each outcome). Of note is the absence of heterogeneity when pooling the results of these outcomes, and this suggests that these outcomes are not so critical in the setting of iron deficiency.

In addition, it must be emphasized that there is lack of published studies that compare oral therapies against specific diet with good iron availability in pregnant women. Guideline

*Correspondence to: Iosief Abraha, Mauro Marchesi Immunotransfusion Service, Perugia Hospital Company, Perugia, Italy, E-mail: iosief_a@yahoo.it

Received: July 16, 2019; Accepted: July 22, 2019; Published: July 29, 2019


Copyright: © 2019 Abraha I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
developers recommend to assess women’s nutritional status before and at the start of pregnancy as both under nutrition and over nutrition can be associated with adverse pregnancy outcomes [15]. With the reviewed moderate evidence reported above, there is a good ground to formulate strong recommendation in favor of oral iron therapy to prevent iron deficiency anemia, but we think that it should be provided after optimized maternal nutrition approach has been insufficient.

REFERENCES